Clinical Trial

Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma

Name: Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma — clinical trial record (NCT07475234)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: RAG-MPDAC

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the efficacy and safety of Rimegepant combined with AG chemotherapy as first-line treatment for metastatic pancreatic cancer.

Trial Details

NCT Number	NCT07475234
Lead Sponsor	Xiuchao Wang
Conditions	Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment	30 participants
Start Date	2026-03
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-16